L A Matis

Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease.

Yijun Wang, Scott A. Rollins, Joseph A. Madri et al. · Proceedings of the National Academy of Sciences · 1995 · 356 citations · Full text

Immunology, Immunotherapy, Inflammatory Arthritis +17

Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5.

Yijun Wang, Qiongzheng Hu, Joseph A. Madri et al. · Proceedings of the National Academy of Sciences · 1996 · 338 citations · Full text

Immunology, Pathology, Immunotherapy +20

Magnitude of response of histocompatibility-restricted T-cell clones is a function of the product of the concentrations of antigen and Ia molecules.

L A Matis, Laurie H. Glimcher, W E Paul et al. · Proceedings of the National Academy of Sciences · 1983 · 310 citations · Full text

Histocompatibility, Immunology, Restriction Elements +19

Peptide-major histocompatibility complex class II complexes with mixed agonist/antagonist properties provide evidence for ligand-related differences in T cell receptor-dependent intracellular signaling.

Luigi Racioppi, Franca Ronchese, L A Matis et al. · The Journal of Experimental Medicine · 1993 · 234 citations · Full text

Ligand-related Differences, T-regulatory Cell, Immunology +20

Identification of distinct predominant epitopes recognized by myoglobin-specific T cells under the control of different <i>Ir</i> genes and characterization of representative T cell clones.

Ira Berkower, L A Matis, G K Buckenmeyer et al. · The Journal of Immunology · 1984 · 103 citations